United States: Fresenius Kabi Announces Launch Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

Thursday, 25 April 2024 (1 week ago)
On April 15, 2024, Fresenius Kabi announced the U.S. launch of its ACTEMRA biosimilar, TYENNE (tocilizumab-aazg) as an intravenous formulation.

👓 View full article

0 shares	Share Tweet Save Post Send

Related videos from verified sources

Nvidia & darpa biohybrid

https://www.youtube.com/watch?v=0Hg7XhbXuac . No One is Talking About What Just Happened..

Credit: Rumble Duration: 55:45Published on March 29, 2024

United States: Fresenius Kabi Announces Launch Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

You Might Like

Related videos from verified sources